BEVERLY DORSEY-FUNK: Open Payments
NPI 1841514890 · FURLONG, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$369 in 16 payments from 9 companies in 2025. Trend: 2023 $125 · 2024 $99 · 2025 $369
Food & beverage: $299Education: $70
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 4 | $93 |
| Regeneron Healthcare Solutions, Inc. | 2 | $87 |
| AstraZeneca Pharmaceuticals LP | 4 | $79 |
| GENZYME CORPORATION | 1 | $26 |
| CSL Behring | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Grifols USA, LLC | 1 | $14 |
Products named: DUPIXENT, TRELEGY ELLIPTA, AIRSUPRA, NUCALA, FASENRA, Andembry, Xolair, TEZSPIRE.
Industry payments across PA — which companies pay providers there.
